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Abstract
Rationale: Bronchopulmonary dysplasia is one of the most serious complications observed in premature infants.
Thanks to microarray technique, expression of nearly all human genes can be reliably evaluated.
Objective: To compare whole genome expression in the first month of life in groups of infants with and without
bronchopulmonary dysplasia.
Methods: 111 newborns were included in the study. The mean birth weight was 1029g (SD:290), and the mean
gestational age was 27.8 weeks (SD:2.5). Blood samples were drawn from the study participants on the 5th, 14th
and 28th day of life. The mRNA samples were evaluated for gene expression with the use of GeneChip® Human
Gene 1.0 ST microarrays. The infants were divided into two groups: bronchopulmonary dysplasia (n=68) and control
(n=43).
Results: Overall 2086 genes were differentially expressed on the day 5, only 324 on the day 14 and 3498 on the day
28. Based on pathway enrichment analysis we found that the cell cycle pathway was up-regulated in the
bronchopulmonary dysplasia group. The activation of this pathway does not seem to be related with the maturity of
the infant. Four pathways related to inflammatory response were continuously on the 5th, 14th and 28th day of life
down-regulated in the bronchopulmonary dysplasia group. However, the expression of genes depended on both
factors: immaturity and disease severity. The most significantly down-regulated pathway was the T cell receptor
signaling pathway.
Conclusion: The results of the whole genome expression study revealed alteration of the expression of nearly 10%
of the genome in bronchopulmonary dysplasia patients.
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Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung disease
associated with premature birth and characterized by early lung
injury [1]. The current consensus is that BPD is a complex
disease, and its pathogenesis depends on the interaction of a
susceptible host with a multitude of environmental risk factors.
The disease is characterized by disturbed alveologenesis. The
many factors that influence alveologenesis include growth
factors, cytokines and other substances that may act as
ligands, receptors, signaling molecules and transcription
factors, and the proteins that are the products of cell activity,
such as enzymes participating in matrix reconstruction,
retinoids and elastin [2–4].
Several experimental trials indicate that growth factors,
especially those associated with vascularization (VEGF-
Vascular endothelial growth factor), are closely related to the
morphological changes in the respiratory tract of children with
BPD [3,5–8]. Researchers are also investigating inflammatory
mediators, such as Tumor Necrosis Factor α (TNF-α),
Interleukin-1β (IL-1β) Interleukin-6 (IL-6), Interleukin-8 (IL-8)
and Interleukin-10 (IL-10) [9–11]. Atypical pathogens,
especially Ureaplasma spp., are believed to play a particular
role in the inflammatory reaction leading to BPD [12,13].
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It is generally agreed that respiratory support in VLBW
infants must be conducted in such a way as to circumvent
damage caused by pressure, volume or oxygen. Results of a
meta-analysis conducted by Stevens et al. demonstrate that
extubation after early surfactant therapy and subsequent
respiratory assistance with nasal continuous positive airway
pressure results in a lower incidence of BPD compared with
selective surfactant therapy and subsequent mechanical
ventilation [14]. Other authors have presented similar
observations favoring less invasive methods of respiratory
assistance and lower ventilation values [15,16]. Oxygen
therapy and the subsequent action of its derivates (free
radicals) has been proven to increase the incidence of BPD
[17,18]. To prevent such complications, practical guidelines
recommending lower blood oxygen saturation values for
preterm babies have been introduced [19,20].
Genetic foundations for the development of BPD are
implicated in twin studies, which reveal highly significant
concordance rates for BPD: 3.69-fold in monozygotic and 1.4-
fold in dizygotic twins [21]. Introduction of the microarray
technique into clinical studies was one of the most important
breakthroughs responsible for the dramatic progress in the field
of human genetics during the last decade. The use of
microarrays has given a new opportunity for studying even 20
000 human genes in a single experiment. The scope of
potential applications of the microarrays is very broad,
combining research and clinical medicine. The greatest
advantage of this method is that it enables assessment of a
great number of genetic factors (practically all human gene
expression) although only a small amount of blood is
necessary for testing, which is very important in preterm
neonates.
To explore the pathogenesis of BPD, we carried out genome
wide transcriptional profiling of RNA extracted from peripheral
blood mononuclear cells of BPD subjects and non-BPD
controls followed by pathway enrichment analysis in an attempt
to identify biological pathways that were preferentially
associated with BPD.
Methods
A prospective study was conducted between September 1,
2008 and November 30, 2010. The entry criteria were (a)
preterm birth < 32 weeks gestational age, (b) birthweight
≤1500g, (c) the need for respiratory support. All patients were
outborn in local hospitals and transported to the Polish
American Children’s Hospital which is a tertiary care unit for the
region.
The majority of patients are referred from first-level neonatal
care hospitals, which provide mainly for rural areas. Detailed
perinatal history (birth weight, gestational age, Apgar score at 1
and 5 minutes after birth) and history of treatment in the referral
hospital (mechanical ventilation, oxygen therapy, surfactant
treatment, diagnoses) were taken on admission. Maternal
fever/infection was used as surrogate for “clinical
chorioamnionitis”. Data on histological chorioamnionitis were
unavailable in most cases. Ureaplasma infection was defined
as positive tracheal aspirate culture for Ureaplasma
urealythicum. The study was approved by the Ethics
Committee of the Jagiellonian University, Faculty of Medicine
(KBET 27/B/2007). Written informed consent was obtained
from all participants involved in the study.
Microarray analysis
After obtaining written informed consent from the parents,
blood samples (0.3 ml) were drawn from all the study
participants on the 5th, 14th and 28th day of life (DOL) for the
assessment of whole genome expression in peripheral blood
leukocytes. Subsequently, Ficoll isopaque gradient
centrifugation (30 min, 2100 rpm, RT), and two times wash in
1x PBS (12 min, 1600 rpm, 40C), and finally RiboPure Blood
Kit (Ambion, Life Technologies, Carlsbad, USA) were used for
total RNA extraction.RNA concentration was measured with the
use of NanoDrop Spectrophotometer (NanoDrop ND-1000;
Thermoscientific, Waltham, USA), and RNA quality was
determined by 2100 Bioanalyzer (Agilent, Santa Clara, USA).
100ng of total RNA were used for the single microarray
experiment. GeneChip Human Gene 1.0 ST Arrays (Affymetrix,
Santa Clara, USA) were used. Whole transcript microarray
experiment was performed according to the manufacturer’s
protocol (GeneChip Whole Transcript sense Target Labeling
Assay Manual, Version 4). The Affymetrix GeneChip Whole
Transcript sense Target Labeling Assay is designed to
generate amplified and biotinylated sense-strand DNA targets
from the entire expressed genome. The protocol is optimized
for use with the GeneChip Sense Target Arrays, where the
probes are distributed throughout the entire length of each
transcript. Details of microarray experiment were presented in
online supplemental file – Appendix S1.
Real-time PCR validation
To validate the results obtained by the microarray analysis
real-time PCR technique was used. A total of 30 cDNA
samples (15 patients with BPD and 15 controls) remaining after
microarray analysis, were used for the validation procedure.
Samples were randomly selected from the studied groups.
From each sample 100ng of cDNA was used for the single
TaqMan Gene Expression Assay. Amplification reaction was
performed with the use of TaqMan Universal PCR Master Mix
and appropriate TaqMan probes (Life Technologies, Carlsbad,
USA). Each sample was analyzed in duplicate.
Average between the expression of endogenous controls
(housekeeping genes: GAPDH and Actin-B) was used for
determination of the relative expression levels with the use
of∆∆Ct calculation.For the validation procedure 14 genes were
randomly selected from the group of genes differentially
expressed in the microarray experiment (fold change greater or
equal to +/-1.5) and from the genes without significant
differences in expression.
Following TaqMan Gene Expression Assays were used:
Hs00900055_m1 (VEGF gene), Hs00952786_m1 (AK5 gene),
Hs00217864_m1 (OLAH gene), Hs01030384_m1 (ILR2 gene),
Hs00187022_m1 (ADAM23 gene), Hs00736937_m1 (DAAM2
gene), Hs00360669_m1 (CD177 gene), Hs00255338_m1
(KLRC4 gene), Hs00171191_m1 (FBN1 gene),
Hs00539582_s1 (LRRN3 gene), Hs00196254_m1 (NELL2
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gene), Hs00924296_m1 (MPO gene), Hs00541549_m1
(ABCA13 gene), Hs00197437_m1 (OLFM4 gene),GAPDH
(Hs02758991_g1) and Actin-B (Hs99999903_m1); (Life
Technologies, Carlsbad, USA).
Outcome variables
Scheduled examinations were performed on all patients. The
procedures of oxygen therapy in the examined group were
consistent throughout the study with the goal of maintaining
hemoglobin saturation between 88 and 95%. BPD severity was
graded according to criteria proposed by Jobe and Bancalari
[22]. Four cohorts of children were identified based on
examination at age 36 weeks post conception or on discharge.
Mild BPD was defined as a need for supplemental oxygen for >
or =28 days but not at 36 weeks' postmenstrual age (PMA) or
discharge; moderate BPD as a need for supplemental oxygen
for > or =28 days plus treatment with <30% oxygen at 36
weeks' PMA, and severe BPD as a need for supplemental
oxygen for > or =28 days plus > or =30% oxygen
supplementation and/or positive pressure at 36 weeks' PMA.
Infants treated with oxygen > 21% and/or positive pressure for
nonrespiratory disease (e.g., central apnea or diaphragmatic
paralysis) were not included in the BPD group unless they also
developed parenchymal lung disease and exhibited clinical
features of respiratory distress. Treatment with oxygen > 21%
and/or positive pressure at 36-week postmenstrual age (PMA)
due to an "acute" event was not a criterion for BPD. The
evaluation of oxygen requirement was performed by a staff
member blinded to molecular studies results.
Statistical analysis
The R package, sizepower was used to calculate sample
size [23]. A completely randomized treatment-control design
was chosen. The total number of probe sets (genes) on the
single microarray was 32323 (GeneChip Human Gene 1.0 ST
Arrays – Affymetrix) and the number of genes that were not
differentially expressed but falsely declared by the test
procedure to be differentially expressed (number of false
positives) was assumed to be about 1%. To simplify
calculations, normal distribution of normalized gene expression
values, the equality of variances and no interaction among
genes were assumed. Based on preliminary data we
anticipated that the variance of log-transformed gene
expression levels should be equal to 0.6. The inclusion of 94
newborns (47 in each group) had power equal to 90% for
detecting differentially expressed genes if significant gene
expression difference was defined as fold expression change
equal or greater than 1.5.
Basic demographic data were compared using the one-way
analysis of variance or Kruskal-Wallis analysis of variance as
appropriate. Qualitative values were compared using the chi-
square test.
Neonatal data used for the study was recorded daily during
hospitalization in NICU in a prospective manner and stored in
computer databases. For the purpose of the study the following
data was used: sex, birthweight, gestational age, intrauterine
growth parameters, Apgar score, incidence of preeclampsia,
maternal diabetes, preterm rupture of membranes,
chorionamnionitis, delivery type, delivery room management,
presence of respiratory distress syndrome (RDS), length of
mechanical ventilation, surfactant administration, use of
ibuprofen for patent ductus arteriosus (PDA), PDA ligation,
early- and late-onset septic episodes, ureaplasma infection,
prevelance of intraventricular haemorrhage (IVH),
periventricular leukomalacia (PVL), weight gain during NICU
stay and length of hospitalization.
The microarray data were pre-processed using the R/
Bioconductor package aroma.affymetrix [24,25]. For
normalization we used Robust Multiarray Average (RMA) [26].
Quality control was performed by investigating Principal
Component Analysis (PCA), Relative Log Expression (RLE)
and Normalized Unscaled Standard Error (NUSE) plots. None
of the arrays were discarded due to poor quality. Details of
quality control analysis were presented in the online
supplemental file – Figure S1-S7 in Appendix S1
Moderated t-tests [27] were performed to detect the probes
that were differentially expressed between groups, using the
limma package [28] in the R statistical software. Multiple testing
correction, using the Benjamini-Hochberg procedure was
applied to control the false discovery rate (FDR) [29]. If a probe
set had an corrected for multiple comparison p-value less than
0.01, it was declared significantly differentially expressed.
The groups differed with respect to birthweight, gestational
age, delivery type, gender, Apgar score, delivery room
intubation, surfactant therapy, prenatal steroids, use of
ibuprofen for patent ductus arteriosus (PDA), PDA ligation,
length of mechanical ventilation). The next step of the analysis
was designed to examine whether the differences in gene
expression between the groups were due to the differences
between the groups with respect to these factors. A linear
model was fitted to the expression data for each probe, and
moderated t-tests and F-statistics were computed for each
contrast. For each probe set that was found to be differentially
expressed between the groups in the first part of the analysis,
we tested whether this expression was explained by the group
indicator and/or by gestational age and/or delivery type,
gender, Apgar score, delivery room intubation, surfactant
therapy, prenatal steroids, patent ductus arteriosus, length of
mechanical ventilation using the function classifyTestsF from
the limma package.
For the four categories of BPD we used Spearman’s rho
statistic [30] to test whether there was a monotonic trend in
gene expression between the categories.
DAVID annotation tools were used to explore which
predefined gene sets were significantly enriched in one group
compared to another [31,32]. The KEGG (Kyoto Encyclopedia
of Genes and Genomes; www.genome.jp/kegg) and Biocarta
pathways (www.biocarta.com) were selected for analysis.
Genes differentially expressed between BPD patients and
controls with p-values adjusted for multiple testing below 0.01
and with fold change greater than 1.5 were used as input for
pathway enrichment analysis in DAVID.
The mean fold change values representing differences in
expression between the BPD group and the control group with
regard to each of the 14 genes selected for validation were
compared between the microarray and the TaqMan Gene
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Expression experiments. The Student’s t-test was used for
evaluating the statistical significance of observed differences
between gene expression.
Results
Characteristic of the studied group
One hundred twenty newborns were included in the study.
The mean birth weight was 1029g (SD: 290), and the mean
gestational age was 27.8 weeks (SD: 2.5). The majority of the
pregnancies were terminated by abrupt deliveries. Only 50
(42%) of the mothers received antenatal steroids. Forty-nine
(41%) were born by vaginal delivery. One hundred fourteen
neonates (95%) required respiratory support. Seventy-three
(61%) newborns received surfactant treatment. During the
follow-up period, nine newborns died before the end of the
study, therefore 111 children were included in the final
analysis.
Bronchopulmonary dysplasia
During the follow-up period, BPD was diagnosed in 68 (61%)
infants, including 40 (36%) children with mild disease, 13 (12%)
with moderate and 15 (13%) with severe BPD. Forty-three
newborns served as a control group (no BPD). The infants in
the BPD group were of significantly lower birthweight and
gestational age. As shown in Table 1 more infants in the BPD
group received surfactant treatment and had persistent ductus
arteriosus.
Whole genome expression
All data was collected and analyzed in the adherence to the
Minimal Information About a Microarray Experiment guidelines.
All primary microarray data was submitted to GEO public
repository and are accessible through GEO Series accession
number GSE32472 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE32472).
A summary of the number of differentially expressed genes
between the control and BPD patients is presented in Table 2.
Overall 2086 genes were differentially expressed on the 5th
DOL, only 324 on the 14th DOL, and 3498 on the 28th DOL.
Generally, in each of the three time points during the first
month of life more genes were under-expressed than over-
expressed in the BPD group. The difference in expression
measured as a fold change ranged between 1.0 and 1.5 in the
majority of genes.
The results of the multivariate analysis are presented in the
Tables 3 and 4. Among 2086 genes differentially expressed on
the 5th day of life, only 255 were differentially expressed due to
BPD alone. Most of the genes were differentially expressed
due to the interaction of two factors: BPD and gestational age.
Similar results were obtained by the analysis of genes
differentially expressed on the 14th and 28th day of life. The
observed differences in gene expression were moderate, only
in a few cases the fold change values were higher than 1.5.
The heatmaps from clustering analysis of genes with known
gene symbol were presented in the online data supplement -
Figures S8-S10 in Appendix S1.
Tables S1, S2 and S3 in Appendix S1 present the one
hundred genes with the highest difference in expression on the
5th, 14th and 28th DOL, respectively. Tables S4, S5 and S6 in
Appendix S1 present results of multivariate analysis - the
Table 1. Comparison of selected demographic data in the
bronchopulmonary dysplasia (BPD) groups and in the
control children.
 
noBPD
(n=43)
Mild BPD
(n=40)
Moderate
BPD (n=13)
Severe
BPD (n=15) P
Birth weight, g (x
±SD)
1245±187 960±244 887±300 736±208 <0.001a
Gestational age
(weeks) (x±SD)
29.8 ±1.4 26.8±1.9 26.8±2.5 25.6±2.4 <0.001a
Female gender 24 (56%) 16 (40%) 5 (38%) 5 (33%) 0.32b
Vaginal delivery /
Cesarean section
11/32 20/20 7/6 8/7 0.02b
Multiple pregnancy 12 (28%) 7 (18%) 2 (15%) 2 (13% 0.51b
Small-for-
gestational-age
infant
4 (9%) 5 (13%) 1 (8%) 5 (33%) 0.1b
Maternal
hypertension
8 (19%) 7 (18%) 2 (15%) 1 (7%) 0.74b
Maternal diabetes 3 (7%) 2 (5%) 0 1 (7%) 0.79b
Maternal fever/
infection prior
delivery
5 (12%) 7 (18%) 3 (23%) 4 (27%) 0.53b
1st minute Apgar
Score (Me; 25-75th
percentile)
5 (4-6) 4 (2-6) 2 (1-5) 2 (1-4) 0.01c
5th minute Apgar
Score (Me; 25-75th
percentile)
7 (6-8) 6 (5-7) 4 (3-5) 6 (5-7) 0.001c
Delivery room
intubation
15 (35%) 28 (70%) 10 (77%) 15 (100%) 0.001b
Surfactant therapy 15 (35%) 29 (73%) 9 (69%) 14 (93%) 0.003b
Initial a/A ratio 0.36±0.2 0.37±0.6 0.07±0.4 0.19±0.1 0.06a
Prenatal steroids 23 (54%) 14 (35%) 3 (23%) 6 (40%) 0.15b
Ureaplasma
infection
3 (7%) 8 (20%) 3 (23%) 4 (27%) 0.28b
Culture-proven
sepsis
16 (37%) 19 (48%) 6 (46%) 6 (40%) 0.47b
Pharmacological
closure of patent
ductus arteriosus
14 (33%) 21 (53%) 9 (69%) 11 (73%) 0.014b
Surgical closure of
patent ductus
arteriosus
1 (2%) 8 (20%) 5 (38%) 9 (60%) <0.001b
Length of
mechanical
ventilation (Me;
25-75th percentile)
2 (0-4) 11 (6-30) 42 (35-51)
70
(44-108)
<0.001c
ap-value for one-way analysis of variance
bp-value for chi-square test
cp-value for Kruskal-Wallis analysis of variance
doi: 10.1371/journal.pone.0078585.t001
Gene Expression Profiling in Preterm Infants
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e78585
genes that were differentially expressed on the 5th, 14th and 28th
DOL due to BPD alone. Among the over-expressed genes,
there were some known factors contributing to the
development of BPD such as growth factors and their
receptors. In the group of under-expressed genes, the majority
were involved in the inflammatory response.
Pathway enrichment analysis
Based on the results presented in Tables 2, 3 and 4, seven
pathway enrichment analysis were performed. A summary of
the analysis is presented in Table 5. The pathway up-regulated
in the group of BPD patients is the cell cycle pathway. The
activation of the cell cycle pathway does not seem to be related
to the maturity of the infant. Detailed results of the cell cycle
activation pathway are presented in Table S7 in Appendix S1.
Four pathways were continuously down-regulated on the 5th,
14th and 28th day of life in the group of BPD patients. However,
expression of the genes assigned to these pathways depended
on both factors: immaturity and disease. Detailed results of the
T cell receptor signaling pathways are presented in Table S8 in
Appendix S1.
Genes expression and BPD severity
To detect the presence of a monotonic trend in gene
expression between the BPD severity groups Spearman’s rho
statistic was used. 1699 genes presented a monotone trend on
the 5th, 1223 on the 14th and 4766 on the 28th day of life. Genes
presenting a monotone trend in gene expression with p-values
adjusted for multiple testing below 0.01 were used as input for
pathway enrichment analysis in DAVID. Pathway enrichment
analysis revealed similar results to those obtained in the two
major groups (no BPD and BPD), see Table 6.
Real-time PCR validation
The microarray quality control was performed as
recommended by Affymetrix. GeneChip Operating Software
built-in algorithms were used for this purpose. All the
microarrays fulfilled the quality criteria. The validation
procedure did not reveal significant differences between the
results obtained with use of microarrays compare to real time
PCR technique Figure 1 gives details on the above analysis.
Discussion
In this whole genome expression study of 5, 14 and 28 days
old newborn children born before 32 weeks of gestation we
have compared children who developed BPD to those without
BPD. The nature of the study was mainly exploratory. We
found a large number of differentially expressed genes
between BPD and non BPD children. However, the difference
in the expression measured as a fold change in the majority
genes ranged between 1.0 and 1.5. The expression of only a
few was twofold increased. Most of the genes were
differentially expressed on the 5th and 28th day of life, and only
a small number on the 14th day of life. More genes in the BPD
group, were under-expressed rather than over-expressed.
When adjusting for gender, gestational age and prenatal
steroid treatment, the largest group of differentially expressed
genes, were differentially expressed due to the combination of
two factors: gestational age and BPD. All this general data are
in accordance with our understanding of BPD. Recently
described attempts to create logistic regression models
directed towards BPD prediction conducted on large patient
cohorts point to prematurity as the most important risk factor of
this condition [33,34].
Detailed analysis of the genes with the highest difference in
expression was performed. Interestingly, in this group of genes
we did not find many of the factors traditionally associated with
the development of BPD (inflammatory mediators, growth
factors).
A different method of evaluation of gene expression
alterations is pathway enrichment analysis. This method can
detect transcriptional programs that are distributed across an
Table 2. Summary of the number of differentially expressed genes between bronchopulmonary dysplasia and control
patients.
Number of differentially expressed genes Day 5 Day 14Day 28
Expressed in
both day 5 and
14
Expressed in both
day 5 and day 28
Expressed in
both day 14 and
day 28
Expressed in all three
measurements
Adjusted p value<0.01 All 2086 324 3498 209 1216 259
197 (Pathway analysis
4)
 Over-expressed 881 96 1394 30 431 58 28
 Under-expressed 1205 228 2104 179 785 201 169
Adjusted p value<0.01
and fold change>1.5
All
266 (Pathway
analysis 1)
53
302 (Pathway
analysis 2)
46
180 (Pathway
analysis 3)
47 45
 Over-expressed 179 12 237 6 106 9 7
 Under-expressed 87 41 65 40 74 38 38
Adjusted p value<0.01
and fold change >2.0
All 40 1 34 1 24 1 1
 Over-expressed 40 1 33 1 24 1 1
 Under-expressed 0 0 1 0 0 0 0
doi: 10.1371/journal.pone.0078585.t002
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entire network of genes yet are subtle at the level of individual
genes. Based on this method we found two groups of pathways
Table 3. Number of differentially expressed genes between
the BPD and control group – results of multivariate
analyses.
Model
Day 5 Adjusted
p value <0.01
Day 14
Adjusted p
value <0.01
Day 28
Adjusted p
value <0.01
Univariate anlysis - BPD 2086 324 3498
BPD and Gestational age (GA)    
BPD only
255 (pathway
analysis 5)
16
199 (pathway
analysis 6
BPD and GA 1583 209 2584
BPD and GA and Prenatal
steroids (PS)
   
BPD only 293 18 213
BPD and GA 961 145 1874
BPD and PS 52 1 24
BPD and GA and PS 559 22 408
BPD and GA and Gender    
BPD only 247 16 178
BPD and GA 1229 156 1724
BPD and Gender 41 1 65
BPD and GA and Gender 235 28 558
BPD and GA and delivery room
intubation (DRI)
   
BPD only 280 17 197
BPD and GA 1204 178 1762
BPD and DRI 43 0 45
BPD and GA and DRI 264 9 477
BPD and GA and surfactant
administration (SA)
   
BPD only 227 12 165
BPD and GA 997 85 1632
BPD and SA 75 5 77
BPD and GA and SA 582 73 607
BPD and GA and 5th min.
Apgar score (AS)
   
BPD only 229 14 203
BPD and GA 404 92 1690
BPD and AS 137 6 41
BPD and GA and AS 1032 104 728
BPD and GA and Patent
ductus arteriosus (PDA)
   
BPD only 241 15 182
BPD and GA 781 86 1239
BPD and PDA 99 3 157
BPD and GA and PDA 652 100 1149
BPD and GA and mechanical
ventilation (MV)
   
BPD only 264 18 155
BPD and GA 1156 36 444
BPD and MV 43 12 476
BPD and GA and MV 324 152 1528
doi: 10.1371/journal.pone.0078585.t003
which were differentially regulated at day 5, 14 and 28 after
birth in infants with BPD. The first is the cell cycle pathway
which seems to be a maturity independent pathway
significantly up-regulated in children with BPD. The second
group included pathways involved in inflammatory response.
These pathways were down-regulated in children with BPD.
The expression of genes involved in these pathways was
related to both maturity and the severity of BPD.
Cell cycle
Pathway enrichment analysis, based on gene expression
fold change indicated the cell cycle pathway as one of the most
up-regulated pathways among the BPD newborns. The genes
assigned to this pathway with the highest fold change values
are genes encoding the family of cyclins (CYCA, CYCE and
CYCB) and cyclin related kinase 1 (CDK1). There was no
difference in the expression of CYCD and CDK4/CDK6, as well
as CDK2 as a partner for cyclin E and A. This situation can be
analyzed from several different aspects. The up-regulation of
the cell cycle pathway might be considered an indicator of an
increased cell mitosis rate and increased cell hyperplasia.
In adult and newborn mice hyperoxia induced expression of
p21 protein responsible for the inhibition of cyclin E dependent
kinase activity. Moreover, results from some earlier animal
experiments indicate that hyperoxia inhibits cell proliferation by
two mechanisms; direct cell toxicity and modulation of G1/S
phase transition [35].
The precise interpretation of our results is difficult in view of
the highly specific character of the cell cycle and the still
elusive knowledge on the gene interactions taking part in these
complicated processes. The majority of cell cycle genes
upregulated in the BPD newborns are involved in the regulation
of G1/S transition (CYCE), S/G2 transition (CYCA and CDK1),
and G2/M transition (CYCB and CDK1). The question can be
raised, however, why neither CYCD nor CDK4 and CDK6
showed overexpression. S/G2 transition is under control of
cyclin A and cyclin depended kinases CDK1 and CDK2. In our
studied group overexpression of only CYCA and CDK1 was
observed. However, based on the experimental studies in
CDK2 knockout mice [36] it was suggested that CDK2 is not
required in the cell cycle progress and might be substituted by
Table 4. Number of differentially expressed genes between
the BPD and control group – results of multivariate
analyses.
Model
Day 5 Adjusted p value
<0.01 and fold change
>1.5
Day 28 Adjusted p
value <0.01 and fold
change >1.5
Univariate anlysis - BPD 266 302
BPD and Gestational age
(GA)
  
BPD only 6 2
BPD and GA 243* 286
*. included in pathway analysis 7
doi: 10.1371/journal.pone.0078585.t004
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CDK1. Finally, the G2-M transition is controlled by the CYCB/
CDK1 complex whose increased expression was observed in
the BPD group.
As the level of cyclin B increases, it is bound to CDK1 and
then transported to the nucleus promoting the beginning of the
M phase. This process can be stopped by the phosphorylation
Table 5. Summary of the seven pathway analysis for the differentially expressed genes between the BPD and control group.
Input to pathway analysis Over-expressed Under-expressed
 Pathway name FDR (%)Pathway name FDR (%)
Genes differentially expressed between BPD patients and controls on the
5th DOL, adjusted for multiple comparison p<0.01; fold change >1.5
Cell cycle 3.71 T cell receptor signaling pathway <0.0001
   Cell adhesion molecules (CAMs) 0.001
   Primary immunodeficiency 0.002
   Intestinal immune network for IgA production 0.015
   Hematopoietic cell lineage 0.018
   Allograft rejection 1.674
   Autoimmune thyroid disease 4.501
Genes differentially expressed between BPD patients and controls on the
28th DOL. adjusted for multiple comparison p<0.01; fold change >1.5
Cytokine-cytokine
receptor interaction
1.47 T cell receptor signaling pathway 0.014
 
Fc gamma R-mediated
phagocytosis
6.60 Primary immunodeficiency 0.026
   Cell adhesion molecules (CAMs) 0.046
   Hematopoietic cell lineage 0.066
   Ribosome 0.070
   Intestinal immune network for IgA production 0.101
   Allograft rejection 0.759
   Autoimmune thyroid disease 2.087
   Viral myocarditis 5.261
   Asthma 8.705
Genes differentially expressed between BPD patients and controls in two
measurements: 5th and 28th DOL; p-values adjusted for multiple testing,
p <0.01; fold change >1.5
Cytokine-cytokine
receptor interaction
1.43 T cell receptor signaling pathway 0.001
   Primary immunodeficiency 0.006
   Hematopoietic cell lineage 0.010
   Cell adhesion molecules (CAMs) 0.084
   Intestinal immune network for IgA production 0.645
Genes differentially expressed between BPD patients and controls in all
three measurements; p-values adjusted for multiple testing, p<0.01
No pathway  T cell receptor signaling pathway <0.0001
   Primary immunodeficiency 0.0003
   Hematopoietic cell lineage 0.005
   Cell adhesion molecules (CAMs) 4.348
Genes differentially expressed between BPD patients and controls on the
5th DOL; p-values adjusted for multiple testing, p<0.01; no fold change
restriction; included only genes differentially expressed due to BPD alone
Cell cycle 0.66 No pathway  
Genes differentially expressed between BPD patients and controls on the
28th DOL, p-values adjusted for multiple testing p<0.01; no fold change
restriction; included only genes differentially expressed due to BPD alone
No pathway  No pathway  
Genes differentially expressed between BPD patients and controls on the
5th DOL; p-values adjusted for multiple testing p<0.01; fold change > 1.5;
excluded genes differentially expressed not due to BPD (based on linear
model including BPD. gestational age, gender and prenatal steroids as
contributing factors for different gene expression)
Cell cycle 2.69 T cell receptor signaling pathway <0.0001
   Cell adhesion molecules (CAMs) 0.0017
   Primary immunodeficiency 0.0027
   Intestinal immune network for IgA production 0.015
   Hematopoietic cell lineage 0.018
Pathways with FDR value less than 10% are shown.
doi: 10.1371/journal.pone.0078585.t005
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Table 6. Pathway enrichment analysis of the genes presented a monotone trend in the gene expression between the BPD
severity groups.
Genes differentially expressed between BPD patients and
controls selected for pathway analysis Over-expressed Under-expressed
 Pathway name FDR (%)Pathway name FDR (%)
5th DOL, p-values adjusted for multiple comparison p<0.01; Cell cycle 0.11 Primary immunodeficiency 0.00007
   T cell receptor signaling pathway 0.00023
   Hematopoietic cell lineage 0.677
14th DOL, p-values adjusted for multiple comparison
p<0.01;
Fc gamma R-mediated phagocytosis 3.32 T cell receptor signaling pathway 0.00001
   Primary immunodeficiency 0.00010
   Hematopoietic cell lineage 0.46630
28th DOL, p-values adjusted for multiple comparison
p<0.01;
Fc gamma R-mediated phagocytosis 0.0005 Aminoacyl-tRNA biosynthesis 0.001
 Chemokine signaling pathway 0.28 RNA degradation 0.009
 Fc epsilon RI signaling pathway 0.48 Primary immunodeficiency 0.025
 Neurotrophin signaling pathway 0.94 Purine metabolism 0.06
 Regulation of actin cytoskeleton 0.97 Pyrimidine metabolism 0.07
 GnRH signaling pathway 1.27 Spliceosome 0.16
 Focal adhesion 4.24 Intestinal immune network for IgA production 1.15
 Lysosome 5.02 T cell receptor signaling pathway 1.36
 Leukocyte transendothelial migration 5.55 Nucleotide excision repair 1.38
 Insulin signaling pathway 6.51 RNA polymerase 1.62
 MAPK signaling pathway 7.48 Asthma 8.26
Pathways with FDR value less than 10% are shown.
doi: 10.1371/journal.pone.0078585.t006
Figure 1.  Validation of the microarray experiment by means of real time PCR.  White bar – results of microarray evaluation,
black bar – results of PCR validation. Table presents p value for Student t-test.
doi: 10.1371/journal.pone.0078585.g001
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of CDK. To protect CDK against this phosphorylation, a specific
phosphatase cdc25 and Wee kinase are needed. In fact both of
the above mentioned genes (CDC25 and WEE) were found to
be over-expressed in the BPD group. These results are
therefore strongly indicative of increased mitotic activity of
leukocytes originating from newborns who developed BPD.
The P53 gene representing the major “sensor” of DNA damage
was under-expressed in the BPD group compared to the
controls, and all genes coding for cyclin kinase inhibitory
proteins like P21, P27, and P57 showed comparable
expression to those of the controls. This data might suggest
that the group of BPD newborns was not exposed to, or was
better protected against the influence of environmental factors
potentially leading to DNA damage.
However, it should be noted that the used microarray
approach could reveal non-specific cell cycle pathway up-
regulation. Some studies showed that there is a striking
similarity between the gene expression responses to a priori
very different phenomena. Abrupt temperature changes,
oxidative stress or the addition of particular molecules are
examples of such perturbations [37,38]. A change in the
amount of nutrients is another example [39].
In summary, these data suggest strong cell mitotic activity in
the group of children who developed BPD compared to the
controls, with weaker indications of activation of DNA repair
mechanisms.
T cell receptor signaling pathway
T cells are activated upon the triggering of T cell receptors by
antigen presenting cells. T cell activation induces a series of
biochemical events that can differentially signal the naive T cell
to enter into a pathway leading to the generation of effector T
cells with the onset of rapid proliferation and production of
effector cytokines; or enter into a state of antigenic non-
responsiveness known as anergy or die by apoptosis [40]. The
T cell response depends on the type of ligand bound to its’
receptors, time of co-operation, presence of co-receptors or co-
inhibitors [41,42].
The production of cytokines is essentially controlled by
transcription factors [43]. In our study, transcription factors and
related pathways were under-expressed in children with BPD.
When the differential expression analysis was adjusted for
gender, gestational age and prenatal steroid treatment, it was
revealed that not only immaturity is responsible for the down-
regulation of genes in this pathway, but also disease severity.
The significance of the finding decreased inflammatory
genes expression might be unknown. However, we can
speculate that decreased expression of T cell receptors may
lead to relative anergy and can be a risk factor for bacterial
translocation and further infection. These findings correspond
with our knowledge that one of the risk factors of BPD is
pulmonary infection [44]. Also, there are data indicating that
expression of genes involved in the T cell receptors signaling
pathway can be decreased by reactive oxygen species [45].
Analysis of single gene expression of the genes involved in
these pathways revealed that some genes from this signaling
pathway were over-expressed in BPD children. All the over-
expressed genes in this signaling pathway belong to a classical
part of the mitogen-activated protein kinase signaling pathway.
These genes can be activated by growth factors or in response
to pro-inflammatory stimuli. This signaling pathway is involved
not only in the differentiation or proliferation of lymphocytes, but
also of other cell lines.
Limitations of the study
This type of study protocol raises the question of whether
gene expression of white blood cells reflects gene expression
in the lung. Investigators collaborating on the MuTHER project
(Multiple Tissue Human Expression Resource) have addressed
this issue by studying gene expression in different tissues in
the same individuals [46]. The researchers collected skin,
subcutaneous fat and peripheral blood from female twins. They
found that overall 50 to 80% the loci identified in one tissue
were estimated to have gene regulatory effects in a
comparison tissue. Another interesting study was conducted by
Rudkowska et al. [47]. The objective of this study was to
validate the use of peripheral blood mononuclear cells for gene
expression analysis as a marker of nutritional intervention as
an alternative to skeletal muscle tissue biopsies. The author
found that 88% (32,341) of transcripts were coexpressed in
both tissues. Importantly, very strong correlation was observed
between transcript expression levels of peripheral blood
mononuclear cells and skeletal muscle tissue biopsies.
There is no data about the relationship between gene
expression analysis in circulating cells and lung tissue,
however we can only speculate, on the grounds that hypoxia/
hyperoxia influences the organism of the newborn as a whole,
that analysis of gene expression within the peripheral blood
leukocytes which are characterized by high mitotic activity, may
reflects gene expression in other cells.
Of note is that the neonatal unit where the study was
conducted accepts a highly selective group of newborns from
primary and secondary referral centers. Thus, the study
focused on a population with a high risk for BPD development.
The specific character of the studied population might have
influenced the results that were obtained; namely they were
biased towards a statistically significant difference. The patient
population may not be applicable to other NICUs (for example:
the low rate of prenatal steroid use), and hence our results may
not be generalizable. Another problem relates to the results of
the statistical analysis in the case of multiple comparisons. If no
correction was applied, multiple testing would increase the
probability of a type I error to 1.0 (100%). Bearing this fact in
mind, the correction for the multiple tests was performed,
however at least 1% of false discovery rate can still be
expected. The estimated power of the study to reveal a 1.5 fold
change difference between the BPD and no BPD groups was
92.8%.
It should be noted that the genome expression profiles
detected in our study may be confounded by limitations related
to the nature of biological systems which are dynamic and
change constantly. The mRNAs are being synthesized and
degraded at its own rate and the gene expression is measured
during the experiment at a steady state. Thus, the presence of
mRNA does not necessarily mean that it was just synthesized
and the inability to detect certain transcripts may be due to their
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quick degradation. In addition, many biologically important
changes do not manifest themselves in alterations of the RNA
levels. Most of the cellular functions are performed by proteins
and alteration to these functions can result not only from
changes in protein levels but also from protein modifications
[48].
Conclusions
The results of this whole genome expression study revealed
alteration of the expression of nearly 10% of the genome in
BPD patients. Most of the differences in expression were
associated with the degree of immaturity of the infant.
However, based on pathway enrichment analysis we found
pathways potentially involved in the pathogenesis of the
disease. These results can be considered in two aspects. One,
by reflecting our current knowledge and two, by providing some
new information on the genes potentially involved in the BPD
patomechanism. The results indicating on the overexpression
of the pathways involving cytokine and theirs receptors,
corroborates the generally accepted concept of the contribution
of inflammatory response to the etiology of BPD. On other
hand however, we observed lower expression of different
immune response pathways, including T cell receptor
pathways. These may point out on the relative
immunedeficiency due to the extreme immaturity of the
newborn. The second aspect of our results indicates some
unknown facts, which may throw a new light on the BPD
patomechanism. This refers to the significant overexpression of
the cell cycle pathway in BPD patients. These findings should
be considered with caution for two reasons. First, the over- and
under-expression of the genes are dynamic process strictly
dependent on the phase of the cell cycle, therefore the
assessment performed at the single time point might be the
resultant of different phases of the examined cells. Second, the
final outcome represented by turning genes on or off is the
result of concerted action of many other genes, mainly
transcription factors, which activity might last too short to be
determined. The above reservations do not change the fact,
however, that the results are of sufficient interest to warrant
further investigation on this subject.
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